Tocagen to Present Clinical and Preclinical Data at Three Scientific Meetings

SAN DIEGO, Nov. 10, 2016 /PRNewswire/ -- Tocagen Inc., a clinical-stage, cancer-selective gene therapy company, today announced updated clinical and preclinical data will be presented at the 21^st Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology (SNO), to be held Nov. 17-20 in Scottsdale, Ariz.; 2^nd CNS Anticancer Drug Discovery And Development Conference, to be held Nov. 16-17 in Scottsdale, Ariz.; and the Society for Immunotherapy of Cancer (SITC) 31^st Annual Meeting, to be held Nov. 11-13 in National Harbor, Md.

Details of the SNO presentations are as follows:

Presentation Type: Podium
Title: Complementary clinical and ancillary data from 123 patients with recurrent high grade glioma from three Phase 1 trials of Toca 511 and Toca FC: Update and justification for a Phase 2/3 trial.
Date and Time: Friday, Nov. 18, 3:35-3:40 p.m. MT
Presenter: Manish Aghi, M.D., Ph.D., associate professor of neurological surgery at University of California, San Francisco

Presentation Type: Poster
Title: Toca 511 and 5-fluorocytosine with checkpoint inhibitors reduced tumor burden in a mouse model of glioma
Date and Time: Friday, Nov. 18, 7:30-9:30 p.m. MT
Presenter: Douglas J. Jolly, Ph.D., executive vice president, research and pharmaceutical development at Tocagen 

Presentation Type: Poster
Title: Investigation of anti-tumor cellular immune response elicited by Toca 511 & Toca FC therapy in a recurrent HGG phase 1 trial
Date and Time: Friday, Nov. 18, 7:30-9:30 p.m. MT
Presenter: Derek Ostertag, Ph.D., department leader of R&D diagnostics at Tocagen

Presentation Type: Poster
Title:  Systematic identification of Toca 511 retrovirus integration sites and mutation profiles in tumor and blood samples from patients undergoing investigational treatment for recurrent high grade glioma correlates with favorable clinical safety profile
Date and Time: Friday, Nov. 18, 7:30-9:30 p.m. MT
Presenter: Daniel Hogan, Ph.D., bioinformatics scientist at Tocagen 

Presentation Type: Poster
Title: Successful cancer-selective gene delivery following intravenous Toca 511 delivery in patients with recurrent high grade glioma (HGG)
Date and Time: Friday, Nov. 18, 7:30-9:30 p.m. MT
Presenter: Jolene Shorr, senior director, clinical science at Tocagen 

Presentation Type: Poster
Title: The Toca 7 Study:  Phase 1b Study of Toca 511, a live gamma retrovirus, and Toca FC, an extended-release formulation of 5-fluorocytosine Combined with Standard of Care in Newly Diagnosed High Grade Glioma (NCT02598011)
Date and Time: Friday, Nov. 18, 7:30-9:30 p.m. MT
Presenter: Tiffany Huang, Ph.D., medical science liaison at Tocagen

Details of the CNS Anticancer Drug Discovery and Development Conference presentations are as follows:

Presentation Type: Podium
Title: Successful cancer-selective gene delivery following intravenous Toca 511 delivery in patients with recurrent high grade glioma (HGG)
Date and Time: Thursday, Nov. 17, 9:07-9:19 a.m. MT
Presenter: Timothy Cloughesy, M.D., director of the University of California, Los Angeles, Neuro-Oncology Program

Presentation Type: Podium
Title: Toca 511 and 5-fluorocytosine with checkpoint inhibitors reduced tumor burden in a mouse model of glioma
Date and Time: Thursday, Nov. 17, 12:15-12:27 p.m. MT
Presenter: Douglas J. Jolly, Ph.D., executive vice president, research and pharmaceutical development at Tocagen 

Details of the SITC presentation are as follows:

Presentation Type: Poster
Title: Gene transfer of cytosine deaminase with Toca 511 and subsequent treatment with 5-fluorocytosine induces anti-tumor immunity
Date and Time: Friday, Nov. 11, 12:15-1:30 p.m. and 6:15-7:30 p.m. ET
Presenter: Leah Mitchell, Ph.D., research scientist at Tocagen

About Tocagen

Tocagen is a clinical-stage, cancer-selective gene therapy company developing first-in-class, broadly applicable product candidates designed to activate a patient's immune system against their own cancer. The company is developing its lead investigational product candidate, Toca 511 (vocimagene amiretrorepvec) & Toca FC (extended-release 5-fluorocytosine), initially for the treatment of recurrent high grade glioma (HGG), a disease with significant unmet medical need. Tocagen has initiated the Phase 2 portion of a randomized, controlled Phase 2/3 clinical trial of Toca 511 & Toca FC in patients with recurrent HGG, which is designed to serve as a potential registrational trial. More information about the clinical trial can be found at www.tocagen.com/toca5. Tocagen has initiated a clinical trial of Toca 511 & Toca FC in metastatic cancers, including colorectal, pancreatic, lung, breast, renal and melanoma. Tocagen obtained Fast Track designation from the U.S. Food and Drug Administration for Toca 511 & Toca FC as a treatment of recurrent HGG and Orphan drug designation for the treatment of glioblastoma multiforme (GBM), a subset of HGG. Tocagen has received grant support from leading brain cancer foundations, including Accelerate Brain Cancer Cure (ABC2), National Brain Tumor Society (NBTS), American Brain Tumor Association (ABTA), Musella Foundation and Voices Against Brain Cancer (VABC). For more information, visit www.tocagen.com or follow @Tocagen.

Logo - http://photos.prnewswire.com/prnh/20160601/374329LOGO

SOURCE Tocagen Inc.

Related Links

http://www.tocagen.com